Zhuhai Sailong Pharmaceutical Co Ltd Total Assets
Zhuhai Sailong Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Zhuhai Sailong Pharmaceutical Co Ltd (002898) holds total assets worth CN¥855.28 Million CNY (≈ $125.15 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Zhuhai Sailong Pharmaceutical Co Ltd market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Zhuhai Sailong Pharmaceutical Co Ltd (2013–2025)
Total assets of Zhuhai Sailong Pharmaceutical Co Ltd from 2013 to 2025. This chart illustrates how Zhuhai Sailong Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See Zhuhai Sailong Pharmaceutical Co Ltd (002898) share price today for real-time trading data and today's change.
Zhuhai Sailong Pharmaceutical Co Ltd - Asset Composition Analysis
Zhuhai Sailong Pharmaceutical Co Ltd Total Assets Breakdown (December 2025)
Zhuhai Sailong Pharmaceutical Co Ltd total assets breakdown as of December 2025. Zhuhai Sailong Pharmaceutical Co Ltd's total assets of CN¥855.28 Million consist of 41.4% current assets and 58.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 7.3% |
| Accounts Receivable | CN¥93.73 Million | 11.3% |
| Inventory | CN¥80.38 Million | 9.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥105.07 Million | 12.6% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Zhuhai Sailong Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 002898 working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zhuhai Sailong Pharmaceutical Co Ltd's current assets represent 41.4% of total assets in 2025, a decrease from 71.5% in 2013.
- Cash Position: Cash and equivalents constituted 7.3% of total assets in 2025, down from 45.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, an increase from 2.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 12.6% of total assets.
Zhuhai Sailong Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Zhuhai Sailong Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Zhuhai Sailong Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.85 | 0.97 | 1.34 |
| Quick Ratio | 0.60 | 0.63 | 1.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-66.27 Million | CN¥-6.57 Million | CN¥72.70 Million |
Zhuhai Sailong Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Zhuhai Sailong Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.93 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 3.0% |
| Total Assets | CN¥832.10 Million |
| Market Capitalization | $9.53 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zhuhai Sailong Pharmaceutical Co Ltd's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Zhuhai Sailong Pharmaceutical Co Ltd's assets grew by 3.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Zhuhai Sailong Pharmaceutical Co Ltd (2013–2025)
The table below shows the annual total assets of Zhuhai Sailong Pharmaceutical Co Ltd from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥832.10 Million ≈ $121.76 Million |
+2.95% |
| 2024-12-31 | CN¥808.22 Million ≈ $118.27 Million |
-0.69% |
| 2023-12-31 | CN¥813.84 Million ≈ $119.09 Million |
-4.03% |
| 2022-12-31 | CN¥847.99 Million ≈ $124.09 Million |
-3.94% |
| 2021-12-31 | CN¥882.78 Million ≈ $129.18 Million |
+8.46% |
| 2020-12-31 | CN¥813.96 Million ≈ $119.11 Million |
-2.63% |
| 2019-12-31 | CN¥835.98 Million ≈ $122.33 Million |
+10.60% |
| 2018-12-31 | CN¥755.84 Million ≈ $110.60 Million |
+5.69% |
| 2017-12-31 | CN¥715.13 Million ≈ $104.65 Million |
+133.97% |
| 2016-12-31 | CN¥305.66 Million ≈ $44.73 Million |
+15.46% |
| 2015-12-31 | CN¥264.73 Million ≈ $38.74 Million |
+39.71% |
| 2014-12-31 | CN¥189.48 Million ≈ $27.73 Million |
+1.65% |
| 2013-12-31 | CN¥186.41 Million ≈ $27.28 Million |
-- |
About Zhuhai Sailong Pharmaceutical Co Ltd
Sailong Pharmaceutical Group Co.,Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, tigecycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, pan… Read more